-
Broadcom Shares Plummet After Wall Street Questions Sudden Acquisition Strategy
Thursday, July 12, 2018 - 1:37pm | 749Broadcom Inc (NASDAQ: AVGO) moved 15 percent lower Thursday on mixed reactions following the announcement it had reached a deal to acquire CA, Inc. (NASDAQ: CA). CA Inc. (also known as CA Technologies) jumped 18 percent higher, realizing most of the 20 percent premium to the July 11 closing price...
-
Analyst: Tetra Technologies Is An 'EBITDA Engine'
Friday, July 6, 2018 - 12:35pm | 314Tetra Technologies, Inc. (NYSE: TTI), a global oil and gas services company, boasts a leading position in three unique end markets which makes it an "EBITDA engine," according to B. Riley FBR. The Analyst B. Riley FBR's Thomas Curran initiated coverage of Tetra Technologies with a Buy...
-
Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run
Friday, July 6, 2018 - 10:59am | 447Arbutus Biopharma Corp (NASDAQ: ABUS) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally. The Analyst B. Riley FBR's Madhu Kumar downgraded Arbutus Biopharma from Buy to Neutral with an unchanged $...
-
B. Riley FBR: 3 Reasons To Buy Alimera Sciences
Friday, June 29, 2018 - 2:50pm | 431Nano-cap pharma company Alimera Sciences Inc (NASDAQ: ALIM) could nearly triple in value for three key reasons, according to B. Riley FBR. The Analyst Analyst Andrew D'Silva initiated coverage of Alimera Sciences with a Buy rating and $2.75 price target. The Thesis Alimera is a...
-
3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy
Thursday, June 28, 2018 - 3:18pm | 400Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target....
-
Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain
Tuesday, June 19, 2018 - 9:34am | 446Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) lost a sell-side bull Tuesday, with a B. Riley FBR analyst praising the company's pipeline but concluding the biotech's positives are priced into the stock. The Analyst B. Riley FBR's Madhu Kumar downgraded Deciphera from Buy to Neutral. The...
-
HomeStreet Cost Cuts Should Result In Higher 2019 Earnings, Analyst Says In Upgrade
Monday, June 11, 2018 - 2:00pm | 287A tough mortgage banking environment will likely lead to cost savings initiatives from HomeStreet Inc (NASDAQ: HMST), which should result in an improved 2019 earnings outlook, according to B. Riley FBR. The Analyst Steve Moss of B. Riley FBR upgraded HomeStreet shares from Neutral to Buy and...
-
Ramaco Resources Holds 25% Upside Potential, Analyst Says In Bullish Initiation
Friday, June 1, 2018 - 11:51am | 352Shares of Ramaco Resources Inc (NASDAQ: METC), a developer of metallurgical coal, have about 24-percent upside potential that's contingent on continued execution by the company, according to B. Riley FBR. The Analyst Analyst Lucas Pipes initiated coverage of Ramaco with a Buy rating...
-
Analysts Applaud Intel's Beat-And-Raise Q1 Earnings
Friday, April 27, 2018 - 4:26pm | 791Large-cap tech names posted strong quarterly results this earnings season, and Intel Corporation (NASDAQ: INTC) was no exception. The chip giant reported 13-percent revenue growth and a 32-percent increase in non-GAAP earnings per share Thursday; the company also raised its full-year revenue and...
-
Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease
Wednesday, March 28, 2018 - 3:20pm | 283An optimistic trial outlook on Clementia Therapeutics, Inc. (NASDAQ: CMTA)’s palovarotene in FOP patients could give the pharmaceutical company a leg up in an unmet market for the treatment of a rare disease, according to B. Riley FBR. The Analyst Madhu Kumar of B. Riley FBR initiated...
-
Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation
Wednesday, March 28, 2018 - 3:09pm | 377Dicerna Pharmaceuticals Inc (NASDAQ: DRNA), a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination of good news and bad news should leave investors on the sidelines, according to B. Riley FBR....
-
After Nvidia Analyst Day, Wall Street Talks AV Testing, Artificial Intelligence, GPUs
Wednesday, March 28, 2018 - 2:48pm | 619NVIDIA Corporation (NASDAQ: NVDA) investors didn’t seem to get what they were hoping for at the tech company's analyst day Tuesday. The stock is now down more than 10 percent in the past two days. Here’s a sampling of what analysts had to say about Nvidia after the company'...
-
Main Street Capital Has The Ingredients For Superior Economic Return, Says B Riley FBR
Wednesday, March 28, 2018 - 11:12am | 381Main Street Capital Corporation (NYSE: MAIN) has materially grown its net asset value and dividend, resulting in a higher return relative to all other business development company peers, according to B Riley FBR. The Analyst Analyst Tim Hayes initiated coverage of Main Street Capital...
-
JD Sports' $588-Million Finish Line Purchase Is Positive For Both Companies
Tuesday, March 27, 2018 - 4:44pm | 641After several months of speculation, Finish Line Inc (NASDAQ: FINL) announced it has been acquired by a U.K. retailer, but not the one that was previously named. JD Sports, known as one of the premier footwear retailers in the U.K., has purchased the Indianapolis-based footwear retailer for $588...
-
BB&T Should Trade At Premium To Other Large-Cap Banks, Says B Riley FBR
Tuesday, March 27, 2018 - 3:05pm | 402BB&T Corporation (NYSE: BBT) shares pulled back along with the broader market last week, although they have recouped part of their losses since then. The Analyst B Riley FBR analyst Steve Moss upgraded shares of BB&T from Neutral to Buy and increased the price target from $55 to $69,...